Antibody and IFN-γ responses induced by a recombinant canarypox vaccine and challenge infection with equine influenza virus

Veterinary Immunology and Immunopathology

Volumn 112, Issue 3-4, 2006, Pages 225-233

  Paillot, R ^a   Kydd, J H ^a   Sindle, T ^a   Hannant, D ^a   Edlund Toulemonde, C ^b   Audonnet, J C ^b   Minke, J M ^b   Daly, J M ^a  

^a ANIMAL HEALTH TRUST   (United Kingdom)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Equine influenza virus; Immunity; Vaccine

Indexed keywords

ANTIBODY; CANARYPOX VIRUS VACCINE; GAMMA INTERFERON; HEMAGGLUTININ; INACTIVATED VACCINE; INFLUENZA VACCINE; LIVE VACCINE; PROTEQFLU; RECOMBINANT VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE; VIRUS VECTOR;

AEROSOL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANOREXIA; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; ASSAY; CANARYPOX VIRUS; CELLULAR IMMUNITY; CONTROLLED STUDY; COUGHING; DEPRESSION; DYSPNEA; EMBRYO; FEMALE; GENE EXPRESSION; HORSE; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNIZATION; IMMUNOSTIMULATION; INFLUENZA; INFLUENZA VIRUS; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN SYNTHESIS; RESPIRATORY TRACT DISEASE; SINGLE RADIAL HEMOLYSIS ASSAY; TEMPERATURE; VACCINATION; VIRUS EXCRETION; VIRUS GENE; VIRUS IMMUNITY; VIRUS INFECTION;

ANIMALS; ANTIBODIES, VIRAL; BODY TEMPERATURE; CANARYPOX VIRUS; HORSE DISEASES; HORSES; INFLUENZA A VIRUS, H3N8 SUBTYPE; INTERFERON TYPE II; LEUKOCYTES, MONONUCLEAR; ORTHOMYXOVIRIDAE INFECTIONS; VACCINATION; VACCINES, SYNTHETIC; VIRAL VACCINES;

CANARYPOX VIRUS; EQUIDAE; EQUINE INFLUENZA VIRUS;

EID: 33745699157     PISSN: 01652427     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vetimm.2006.02.007     Document Type: Article

References (22)

1. Breathnach C.C., Rudersdorf R., and Lunn D.P. Use of recombinant modified vaccinia Ankara viral vectors for equine influenza vaccination. Vet. Immunol. Immunopathol. 98 (2004) 127-136
2. Breathnach C.C., Soboll G., Suresh M., and Lunn D.P. Equine herpesvirus-1 infection induces IFN-gamma production by equine T lymphocyte subsets. Vet. Immunol. Immunopathol. 103 (2005) 207-215
3. Edlund Toulemonde C., Daly J., Sindle T., Guigal P.M., Audonnet J.C., and Minke J.M. Efficacy of a recombinant equine influenza vaccine against challenge with an American lineage H3N8 influenza virus responsible for the 2003 outbreak in the United Kingdom. Vet. Rec. 156 (2005) 367-371
4. Gotch F., McMichael A., Smith G., and Moss B. Identification of viral molecules recognized by influenza-specific human cytotoxic T lymphocytes. J. Exp. Med. 165 (1987) 408-416
5. Hannant D., Jessett D.M., O'Neill T., Sundquist B., and Mumford J.A. Nasopharyngeal, tracheobronchial, and sytemic immune responses to vaccination and aerosol infection with equine-2 influenza A virus (H3N8). In: Powell D.G. (Ed). Equine Infectious Diseases V: Proceedings of the Fifth International Conference (1987), University Press of Kentucky, Lexington, KY 66-73
6. Hannant D., Mumford J.A., and Jessett D.M. Duration of circulating antibody and immunity following infection with equine influenza virus. Vet. Rec. 122 (1988) 125-128
7. Livesay G.J., O'Neill T., Hannant D., Yadav M.P., and Mumford J.A. The outbreak of equine influenza (H3N8) in the United Kingdom in 1989: diagnostic use of an antigen capture ELISA. Vet. Rec. 133 (1993) 515-519
8. Minke J.M., Fischer L., Baudu P., Guigal P.M., Sindle T., Mumford J.A., and Audonnet J.C. Use of DNA and recombinant canarypox (ALVAC) vectors for equine herpes vaccination. Vet. Immunol. Immunopathol 111 (2006) 47-57
9. Minke J.M., Siger L., Karaca K., Austgen L., Gordy P., Bowen R., Renshaw R.W., Loosmore S., Audonnet J.C., and Nordgren B. Recombinant canarypoxvirus vaccine carrying the prM/E genes of West Nile virus protects horses against a West Nile virus-mosquito challenge. Arch. Virol. Suppl. (2004) 221-230
10. Moss B. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 11341-11348
11. Mumford J.A., Jessett D.M., Rollinson E.A., D.F H., and Draper M.E. Duration of protective efficacy of equine influenza immunostimulating complex/tetanus vaccines. Vet. Rec. 134 (1994) 158-162
12. Mumford J.A., and Wood J. Establishing an acceptability threshold for equine influenza vaccines. Dev. Biol. Stand. 79 (1992) 137-146
13. Newton J.R., Daly J.M., Spencer L., and Mumford J.A. Description of the 2003 UK equine influenza outbreak when recent vaccination failed to prevent infection of horses in Newmarket. Vet. Rec. 158 (2006) 185-192
14. OIE. Conclusions and recommendations from the consultation of OIE and WHO experts on equine influenza, Newmarket, United Kingdom, September 18-19, 1995. OIE Bulletin vol. 108 (1996) pp. 482-484
15. Paillot R., Daly J., Juillard V., Minke J.M., Hannant D., and Kydd J.H. Equine interferon gamma synthesis in lymphocytes after in vivo infection and in vitro stimulation with EHV-1. Vaccine 23 (2005) 4541-4551
16. Paillot R., Ellis S.A., Daly J., Audonnet J.C., Minke J.M., Davis-Poynter N., Hannant D., and Kydd J.H. Characterisation of CTL and IFN-γ synthesis in ponies following vaccination with a NYVAC-based construct coding for EHV-1 immediate early gene, followed by challenge infection. Vaccine 24 (2006) 1490-1500
17. Paoletti E. Applications of pox virus vectors to vaccination: an update. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 11349-11353
18. Plotkin S.A., Cadoz M., Meignier B., Meric C., Leroy O., Excler J.L., Tartaglia J., Paoletti E., Gonczol E., and Chappuis G. The safety and use of canarypox vectored vaccines. Dev. Biol. Stand. 84 (1995) 165-170
19. Santra S., Schmitz J.E., Kuroda M.J., Lifton M.A., Nickerson C.E., Lord C.I., Pal R., Franchini G., and Letvin N.L. Recombinant canarypox vaccine-elicited CTL specific for dominant and subdominant simian immunodeficiency virus epitopes in rhesus monkeys. J. Immunol. 168 (2002) 1847-1853
20. Soboll G., Horohov D.W., Aldridge B.M., Olsen C.W., McGregor M.W., Drape R.J., Macklin M.D., Swain W.F., and Lunn D.P. Regional antibody and cellular immune responses to equine influenza virus infection, and particle mediated DNA vaccination. Vet. Immunol. Immunopathol. 94 (2003) 47-62
21. Townsend H.G., Penner S.J., Watts T.C., Cook A., Bogdan J., Haines D.M., Griffin S., Chambers T., Holland R.E., Whitaker-Dowling P., Youngner J.S., and Sebring R.W. Efficacy of a cold-adapted, intranasal, equine influenza vaccine: challenge trials. Equine Vet. J. 33 (2001) 637-643
22. Wood J.M., Mumford J.A., Folkers C., Scott A.M., and Schild G.C. Studies with inactivated equine influenza vaccine I. Serological responses of ponies to graded doses of vaccine. J. Hyg. (Lond.) 90 (1983) 371-384